Cadherin-6, Preeclampsia, Pregnancy Biomarker
Conditions
Keywords
second trimester screening, preeclampsia, cadherin-6
Brief summary
Preeclampsia is a pregnancy-specific hypertensive disorder that remains one of the leading causes of maternal and perinatal morbidity and mortality worldwide. Despite extensive research, reliable biomarkers for the early prediction of preeclampsia are still limited. Early identification of pregnancies at risk is clinically important because preventive interventions such as low-dose aspirin therapy may reduce the incidence and severity of the disease. Cadherin-6 (CDH-6) is a calcium-dependent cell adhesion molecule involved in trophoblast invasion and placental development. Abnormal trophoblast differentiation and impaired spiral artery remodeling are key mechanisms implicated in the pathophysiology of preeclampsia. Therefore, molecules involved in placental cell adhesion may have potential as predictive biomarkers for this condition. This prospective observational cohort study aims to investigate whether maternal serum CDH-6 levels measured during the early second trimester of pregnancy (15-20 weeks of gestation) can predict the subsequent development of preeclampsia. Maternal blood samples collected during routine antenatal screening will be analyzed using an enzyme-linked immunosorbent assay (ELISA) to determine CDH-6 concentrations. Pregnancy outcomes will be evaluated and compared between women who develop preeclampsia and those with uncomplicated pregnancies. The findings of this study may provide evidence regarding the predictive value of CDH-6 as an early biomarker for preeclampsia and contribute to improved risk stratification and earlier preventive strategies in pregnancy.
Detailed description
This observational cohort study was retrospectively registered at Clinical Trials.gov.
Interventions
OTHERMaternal serum cadherin-6 measurement
Measurement of maternal serum cadherin-6concentrations using ELİSA in blood samples collected between 15 and 20 weeks of gestation.
Sponsors
Samsun University
Samsun Education and Research Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
* Pregnant women aged 18-40 years * Singleton pregnancy * Gestational age between 15 and 20 weeks confirmed by first-trimester ultrasound * Availability of stored maternal serum samples * Written informed consent
Exclusion criteria
* Chronic hypertention * Pregestational diabetes mellitus * Renal disease * Multiple pregnancy * Smoking or alcohol use * Fetal structural or chromosomal anomalies * İmmunsuppressive treatment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Development of preeclampsia, Diagnosis of preeclampsia defined as systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg after 20 weeks of gestation accompanied by proteinuria or signs of end-organ dysfunction. | During pregnancy until delivery |
Secondary
| Measure | Time frame |
|---|---|
| Concentration of maternal serum CDH-6 | within one week of being diagnosed with preeclampsia |
Countries
Turkey (Türkiye)
Outcome results
None listed